Skip to main content
VulnerabilityPublished

CVE-2025-64642: Mirion Medical EC2 Software NMIS BioDose · Incorrect Permissions

Affects Mirion Medical EC2 Software NMIS BioDoseSource CVE Database V5

0

Not known to be exploited · CVSS 7.1 High.

Data as of 26 Oct 2026, 15:59 UTC

CVSS 4.0 base score
7.1High
How severe the flaw is on the 0–10 CVSS scale.
EPSS
0.1% chance of exploitation in 30 days – higher than 1% of CVEsExploit Prediction Scoring System: the likelihood attackers will use this flaw soon.
CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:N/VC:L/VI:H/VA:H/SC:N/SI:N/SA:N

Exploitation evidence

  1. Disclosed: evidence found.

    CVE published 2 Dec 2025

  2. Detectable: no evidence on record.

    No public nuclei template indexed

  3. Weaponised: no evidence on record.

    No public exploit code indexed in Metasploit or Exploit-DB

  4. Exploited in the wild: no evidence on record.

    Not in CISA KEV and no source reports exploitation

  5. Observed by OffSeq Mirage: no evidence on record.

    No attack traffic recorded by OffSeq Mirage sensors

A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 26 Oct 2026.

What to do

Affected software

ProductAffectedFixed in
Mirion Medical EC2 Software NMIS BioDoseAffected
  • =0
Fixed in–

AI-suggested

To mitigate CVE-2025-64642, organizations should immediately audit the file and directory permissions of the NMIS BioDose installation paths on all client workstations and servers. Permissions must be restricted to trusted administrators only, removing write access from standard users or any non-administrative accounts. Implementing strict access control lists (ACLs) and leveraging operating system security features such as Windows Group Policy or Linux file permission models can enforce these restrictions. Additionally, organizations should monitor file integrity using tools like tripwire or OS-integrated file integrity monitoring to detect unauthorized changes promptly. Since no patches are currently available, configuration hardening is critical. Limiting local access to authorized personnel and employing endpoint security solutions to detect suspicious activity can further reduce risk. Regular backups of the software and configuration files should be maintained to enable recovery in case of tampering. Finally, organizations should engage with Mirion Medical for updates and patches and consider applying any vendor-recommended security configurations as they become available.

Description

CVE-2025-64642 is a high-severity vulnerability in Mirion Medical's EC2 Software NMIS BioDose (version 22.02 and earlier) where installation directories have insecure file permissions. This misconfiguration allows local users on client workstations to modify critical program executables and libraries without requiring authentication or user interaction. Exploiting this vulnerability could lead to privilege escalation, code tampering, or disruption of medical dose measurement operations. Although no known exploits are reported in the wild yet, the vulnerability poses a significant risk to the integrity and availability of the affected software. European healthcare organizations using this software are particularly at risk due to the critical nature of medical radiation dose monitoring. Mitigation requires immediate review and correction of file permissions on installation directories, restricting write access to trusted administrators only. Countries with advanced healthcare infrastructure and known deployments of Mirion Medical products, such as Germany, France, the UK, and the Netherlands, are most likely to be impacted. Given the ease of local exploitation and high impact on system integrity and availability, this vulnerability is rated as high severity. Defenders should prioritize patching or applying configuration hardening to prevent unauthorized modifications.

References

Community reviews

Loading reviews…